Advertisement

If the Platelets Are Low, Is It HIT?

  • Theodore E. WarkentinEmail author
Chapter
Part of the Difficult Decisions in Surgery: An Evidence-Based Approach book series (DDSURGERY)

Abstract

Intraoperative heparin exposure and intra-/postoperative thrombocytopenia occur universally with cardiac surgery. Sometimes, heparin triggers formation of highly pathological platelet-activating antibodies that cause thrombocytopenia, hypercoagulability, and greatly increased risk of venous and/or arterial thrombosis beginning approximately 1 week post-surgery, a disorder called heparin-induced thrombocytopenia (HIT). The challenge is to distinguish HIT from the myriad of non-HIT thrombocytopenic disorders common to this patient population. The characteristic timing of HIT, and its hallmark of associated thrombosis, means that any otherwise unexplained platelet count fall of >40% (especially with associated thrombotic event) that begins during the characteristic day 5–10 “window” post-cardiac surgery should be presumed to be HIT unless proven otherwise. In contrast, early-onset and persisting thrombocytopenia following cardiac surgery is unlikely to be HIT. Growing recognition that HIT can begin or worsen after all heparin has been stopped (“autoimmune HIT”) indicates that this diagnosis should be considered even when thrombocytopenia or thrombosis is recognized up to 1 month following cardiac surgery.

Keywords

Autoimmune Heparin HIT antibodies Thrombocytopenia Thrombosis 

References

  1. 1.
    Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg. 2003;76(6):2121–31.PubMedGoogle Scholar
  2. 2.
    Warkentin TE, Greinacher A, Gruel Y, Aster RH, Chong BH, Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. J Thromb Haemost. 2011;9(12):2498–500.PubMedGoogle Scholar
  3. 3.
    Warkentin TE. Heparin-induced thrombocytopenia, part 2: clinical course and treatment. J Crit Illn. 2005;20(2):36–43.Google Scholar
  4. 4.
    Warkentin TE. Heparin-induced thrombocytopenia in critically ill patients. Semin Thromb Hemost. 2015;41(1):49–60.PubMedGoogle Scholar
  5. 5.
    Warkentin TE, Sheppard JI. Clinical sample investigation (CSI) hematology: pinpointing the precise onset of heparin-induced thrombocytopenia (HIT). J Thromb Haemost. 2007;5(3):636–7.PubMedGoogle Scholar
  6. 6.
    Warkentin TE, Moore JC, Vogel S, Sheppard JI, Warkentin NI, Eikelboom JW. The serological profile of early-onset and persisting post-cardiac surgery thrombocytopenia complicated by “true” heparin-induced thrombocytopenia. Thromb Haemost. 2012;107(5):998–1000.PubMedGoogle Scholar
  7. 7.
    Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia. 5th ed. Boca Raton: CRC Press; 2013. p. 24–76.Google Scholar
  8. 8.
    Warkentin TE, Sheppard JI, Moore JC, Cook RJ, Kelton JG. Studies of the immune response in heparin-induced thrombocytopenia. Blood. 2009;113(20):4963–9.PubMedGoogle Scholar
  9. 9.
    Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344(17):1286–92.PubMedGoogle Scholar
  10. 10.
    Shih AW, Sheppard JI, Warkentin TE. Platelet count recovery and seroreversion in immune HIT despite continuation of heparin: further observations and literature review. Thromb Haemost. 2017;117(10):1868–74.PubMedGoogle Scholar
  11. 11.
    Kopolovic I, Warkentin TE. Progressive thrombocytopenia after cardiac surgery in a 67-year-old man. CMAJ. 2014;186(12):929–33.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med. 2001;135(7):502–6.PubMedGoogle Scholar
  13. 13.
    Levine RL, Hursting MJ, Drexler A, Lewis BE, Francis JL. Heparin-induced thrombocytopenia in the emergency department. Ann Emerg Med. 2004;44(5):511–5.PubMedGoogle Scholar
  14. 14.
    Jackson MR, Neilson WJ, Lary M, Baay P, Web K, Clagett GP. Delayed-onset heparin-induced thrombocytopenia and thrombosis after intraoperative heparin anticoagulation. Four case reports. Vasc Endovasc Surg. 2006;40(1):67–70.Google Scholar
  15. 15.
    Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost. 2017;15(11):2099–114.PubMedGoogle Scholar
  16. 16.
    Nguyen TH, Medvedev N, Delcea M, Greinacher A. Anti-platelet factor 4/polyanion antibodies mediate a new mechanism of autoimmunity. Nat Commun. 2017;8:14945.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Khoury M, Pitsis A, Poumpouridou-Kioura H, Soufla G, Kanthou C, Matoula N, et al. Acute intraoperative heparin-induced thrombocytopenia (HIT) and thrombosis during coronary artery bypass grafting: two case reports providing evidence for the role of preoperative LMWH in triggering sensitization. Thromb Res. 2016;146:126–30.PubMedGoogle Scholar
  18. 18.
    Antoniou T, Stavridis G, Daganou M, Melissari E, Gatzonis S. Heparin-induced thrombocytopenia thrombosis after cardiac surgery. A case report. Acta Anaesthesiol Scand. 2000;44(8):991–3.PubMedGoogle Scholar
  19. 19.
    Saltman AE, Dzik WH, Levitsky S. Immediate vein graft thrombectomy for acute occlusion after coronary artery bypass grafting. Ann Thorac Surg. 1999;67(6):1775–6.PubMedGoogle Scholar
  20. 20.
    Warkentin TE. Acute intraoperative HIT during heart surgery: why so rare? Thromb Res. 2016;146:110–2.PubMedGoogle Scholar
  21. 21.
    Zucker MJ, Sabnani I, Baran DA, Balasubramanian S, Camacho M. Cardiac transplantation and/or mechanical circulatory support device placement using heparin anti-coagulation in the presence of acute heparin-induced thrombocytopenia. J Heart Lung Transplant. 2010;29(1):53–60.PubMedGoogle Scholar
  22. 22.
    Warkentin TE, Pai M, Linkins LA. Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. Blood. 2017;130(9):1104–13.PubMedGoogle Scholar
  23. 23.
    Warkentin TE. Heparin-induced thrombocytopenia and the anesthesiologist. Can J Anesth. 2002;49(6; Suppl):S36–49.PubMedGoogle Scholar
  24. 24.
    Pouplard C, May MA, Iochmann S, Amiral J, Vissac AM, Marchand M, et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulation with unfractionated heparin or a low-molecular-weight heparin. Clinical implications for heparin-induced thrombocytopenia. Circulation. 1999;99(19):2530–6.PubMedGoogle Scholar
  25. 25.
    Warkentin TE, Sheppard JI, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96(5):1703–8.PubMedGoogle Scholar
  26. 26.
    Pouplard C, May MA, Regina S, Marchand M, Fusciardi J, Gruel Y. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. Br J Haematol. 2005;128(6):837–41.PubMedGoogle Scholar
  27. 27.
    Selleng S, Malowsky B, Strobel U, Wessel A, Ittermann T, Wollert HG, et al. Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia even when antibody tests are positive. J Thromb Haemost. 2010;8(1):30–6.PubMedGoogle Scholar
  28. 28.
    Lillo-Le Louët A, Boutouyrie P, Alhenc-Gelas M, et al. Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass. J Thromb Haemost. 2004;2(11):1882–8.PubMedGoogle Scholar
  29. 29.
    Selleng S, Selleng K, Wollert HG, Muellejans B, Lietz T, Warkentin TE, et al. Heparin-induced thrombocytopenia in patients requiring prolonged intensive care unit treatment after cardiopulmonary bypass. J Thromb Haemost. 2008;6:428–35.PubMedGoogle Scholar
  30. 30.
    Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med. 2003;163(20):2518–24.PubMedGoogle Scholar
  31. 31.
    Warkentin TE. HITlights: a career perspective on heparin-induced thrombocytopenia. Am J Hematol. 2012;87(Suppl. 1):S92–9.PubMedGoogle Scholar
  32. 32.
    Kuitunen A, Suojaranta-Ylinen R, Raivio P, Kukkonen S, Lassila R. Heparin-induced thrombocytopenia following cardiac surgery is associated with poor outcome. J Cardiothorac Vasc Anesth. 2007;21(1):18–22.PubMedGoogle Scholar
  33. 33.
    Warkentin TE. Ischemic limb gangrene with pulses. N Engl J Med. 2015;373(7):642–55.PubMedGoogle Scholar
  34. 34.
    Josa M, Siouffi SY, Silverman AB, Barsamian EM, Khuri SF, Sharma GV. Pulmonary embolism after heart surgery. J Am Coll Cardiol. 1993;21(4):990–6.PubMedGoogle Scholar
  35. 35.
    Liu JC, Lewis BE, Steen LH, Grassman ED, Bakhos M, Blakeman B, et al. Patency of coronary artery bypass grafts in patients with heparin-induced thrombocytopenia. Am J Cardiol. 2002;89(8):979–81.PubMedGoogle Scholar
  36. 36.
    Warkentin TE, Sheppard JI, Sun JCJ, Jung H, Eikelboom JW. Anti-PF4/heparin antibodies and venous graft occlusion in postcoronary artery bypass surgery patients randomized to postoperative unfractionated heparin or fondaparinux thromboprophylaxis. J Thromb Haemost. 2013;11(2):253–60.PubMedGoogle Scholar
  37. 37.
    Gluckman TJ, Segal JB, Schulman SP, et al. Effect of anti-platelet factor-4/heparin antibody induction on early saphenous vein graft occlusion after coronary artery bypass surgery. J Thromb Haemost. 2009;7(9):1457–64.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Welsby IJ, Krakow EF, Heit JA, et al. The association of anti-platelet factor 4/heparin antibodies with early and delayed thromboembolism after cardiac surgery. J Thromb Haemost. 2016;15(1):57–65.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Bakaeen FG, Walkes JC, Reardon MJ. Heparin-induced thrombocytopenia associated with bilateral adrenal hemorrhage after coronary artery bypass surgery. Ann Thorac Surg. 2005;79(4):1388–90.PubMedGoogle Scholar
  40. 40.
    Hong AP, Cook DJ, Sigouin CS, Warkentin TE. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood. 2003;101(8):3049–51.PubMedGoogle Scholar
  41. 41.
    Teh CH, Robertson MN, Warkentin TE, Henriksen PA, Brackenbury ET, Anderson JAM. Transient global amnesia as the presenting feature of heparin-induced thrombocytopenia. J Card Surg. 2010;25(3):300–2.PubMedGoogle Scholar
  42. 42.
    Warkentin TE, Greinacher A. Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes. Expert Opin Drug Saf. 2009;8(2):129–44.PubMedGoogle Scholar
  43. 43.
    Thielmann M, Bunschkowski M, Tossios P, Selleng S, Marggraf G, Greinacher A, et al. Perioperative thrombocytopenia in cardiac surgical patients – incidence of heparin-induced thrombocytopenia, morbidities and mortality. Eur J Cardiothorac Surg. 2010;37(6):1391–5.PubMedGoogle Scholar
  44. 44.
    Bakchoul T, Jouni R, Warkentin TE. Protamine (heparin)-induced thrombocytopenia: a review of the serological and clinical features associated with anti-protamine/heparin antibodies. J Thromb Haemost. 2016;14(9):1685–95.PubMedGoogle Scholar
  45. 45.
    Saltzman DJ, Chang JC, Jimenez JC, Carson JG, Abolhoda A, Newman RS, Milliken JC. Postoperative thrombotic thrombocytopenic purpura after open heart operations. Ann Thorac Surg. 2010;89(1):119–23.PubMedGoogle Scholar
  46. 46.
    Jubelirer SJ, Ratliff HL, Cotes DJ, Riley MA, Welch CA. Thrombotic thrombocytopenic purpura (TTP) following coronary artery bypass: case series and review of the literature. W V Med J. 2015;111(1):10–4.PubMedGoogle Scholar
  47. 47.
    Warkentin TE, Anderson JAM. DITP causation: 3 methods better than 1? Blood. 2010;116(12):2002–3.PubMedGoogle Scholar
  48. 48.
    Warkentin TE. Drug-induced immune-mediated thrombocytopenia—from purpura to thrombosis. N Engl J Med. 2007;356(9):891–3.PubMedGoogle Scholar
  49. 49.
    Lubenow N, Eichler P, Albrecht D, Carlsson LE, Kothmann J, Rossocha WR, Hahn M, Quitmann H, Greinacher A. Very low platelet counts in post-transfusion purpura falsely diagnosed as heparin-induced thrombocytopenia. Report of four cases and review of literature. Thromb Res. 2000;100(3):115–25.PubMedGoogle Scholar
  50. 50.
    Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332(20):1330–5.PubMedGoogle Scholar
  51. 51.
    Warkentin TE, Sheppard JI, Heels-Ansdell D, Marshall JC, McIntyre L, Rocha MG, et al. Heparin-induced thrombocytopenia in medical surgical critical illness. Chest. 2013;144(3):848–58.PubMedGoogle Scholar
  52. 52.
    Piednoir P, Allou N, Provenchère S, Berroeta C, Huise MG, Philip I, et al. Heparin-induced thrombocytopenia after cardiac surgery: an observational study of 1,722 patients. J Cardiothorac Vasc Anesth. 2012;26(4):585–90.PubMedGoogle Scholar
  53. 53.
    Bucci C, Geerts WH, Sinclair A, Fremes SE. Comparison of the effectiveness and safety of low-molecular-weight heparin versus unfractionated heparin anticoagulation after heart valve surgery. Am J Cardiol. 2011;107(4):591–4.PubMedGoogle Scholar
  54. 54.
    Warkentin TE, Sheppard JI, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood. 2006;108(9):2937–41.PubMedGoogle Scholar
  55. 55.
    Warkentin TE, Linkins LA. Non-necrotizing heparin-induced skin lesions and the 4T’s score. J Thromb Haemost. 2010;8(7):1483–5.PubMedGoogle Scholar
  56. 56.
    Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):340S–80S.PubMedGoogle Scholar
  57. 57.
    Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e495S–530S.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost. 2008;6(8):1304–12.PubMedGoogle Scholar
  59. 59.
    Warkentin TE, Arnold DM, Nazi I, Kelton JG. The platelet serotonin-release assay. Am J Hematol. 2015;90(6):564–72.PubMedGoogle Scholar
  60. 60.
    Warkentin TE, Sheppard JI, Linkins LA, Arnold DM, Nazy I. Performance characteristics of an automated latex immunoturbidimetric assay [HemosIL® HIT-Ab(PF4-H)] for the diagnosis of immune heparin-induced thrombocytopenia. Thromb Res. 2017;153:108–17.PubMedGoogle Scholar
  61. 61.
    Warkentin TE, Pai M, Sheppard JI, Schulman S, Spyropoulos AC, Eikelboom JW. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost. 2011;9(12):2389–96.PubMedGoogle Scholar
  62. 62.
    Warkentin TE. Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls. Exp Opin Drug Saf. 2014;13(1):25–43.Google Scholar
  63. 63.
    Warkentin TE, Davidson BL, Büller HR, Gallus A, Gent M, Lensing AWA, et al. Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE. Chest. 2011;140(2):366–73.PubMedGoogle Scholar
  64. 64.
    Warkentin TE, Sheppard JI. Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are reexposed to heparin. Blood. 2014;123(16):2485–93.PubMedGoogle Scholar
  65. 65.
    Warkentin TE, Anderson JAM. How I treat patients with a history of heparin-induced thrombocytopenia. Blood. 2016;128(3):348–59.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Pathology and Molecular Medicine, and Department of Medicine, Michael G. DeGroote School of MedicineMcMaster UniversityHamiltonCanada
  2. 2.Hamilton Regional Laboratory Medicine Program, Hamilton Health SciencesHamilton General HospitalHamiltonCanada

Personalised recommendations